Lead Sponsor

Alnylam Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Received liver transplant for treatment of hATTR amyloidosis ≥12 months before study start
•Has increase in polyneuropathy disability (PND) score after liver transplant
•Has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start
•Has Karnofsky Performance Status (KPS) of ≥70%
•Has vitamin A level greater than or equal to lower limit of normal

•Has previously received inotersen or patisiran
•Has clinically significant liver function test abnormalities
•Has known portal hypertension with ascites
•Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m\^2
•Has known leptomeningeal amyloidosis
•Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
•Has New York Heart Association heart failure classification of \>2
•Is wheelchair bound or bedridden
•Has received organ transplants other than liver transplant
•Will be using another tetramer stabilizer during the study